Biopharmaceutical Co. Investor Contests Director Pay In Del.
Shareholders of small cap venture Reata Biopharmaceuticals Inc. have accused the company's directors of squandering cash on excessive director pay despite years of unbroken steep net losses, in a Delaware Chancery...To view the full article, register now.
Already a subscriber? Click here to view full article